[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"respiratory-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:respiratory-infection":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,45,71,100,127,167],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100448768","phase-2-phase-2a-multiple-ascending-dose-study-in-hospitalized-patients-with-pneumonia-100448768",false,"NCT05123755","Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia.","A Randomized, Double-blind, Placebo-controlled, Phase 2a Multiple Ascending Dose Study to Examine the Safety, Tolerability and Efficacy of AV-001 Injection in Patients Hospitalized With Pneumonia Due To COVID-19 or Other Respiratory Infections.","Inclusion Criteria:\n\n* Able and willing to give signed informed consent\n* Patients hospitalized with a presumed diagnosis of pneumonia of \\\u003C 48 hours duration requiring supplemental oxygen therapy. Eligible patients include those hospitalized for a separate non-infectious reason who subsequently develop a presumed pneumonia;\n* Radiologic imaging (chest x-ray, CT scan, etc.) evidence of pulmonary involvement with new and persistent or progressive and persistent infiltrate, consolidation or cavitation.\n\nSigns and symptoms:\n\nAt least 1 of the following signs:\n\n* respiratory rate \\> 30 breaths\u002Fmin;\n* fever (\\> 38.0ºC or \\> 100.4o F);\n* leukopenia (≤ 4,000 WBC\u002Fmm3 or leukocytosis (≥ 12,000 WBC\u002Fmm3);\n* adults ≥ 70 years of age; altered mental status with no other recognized cause;\n\nAND at least 1 of the following symptoms:\n\n* New onset of purulent sputum or change in character of sputum or increased respiratory secretions;\n* New onset or worsening cough, or dyspnea, or tachypnea;\n* Rales or bronchial breath sounds;\n\n  * Female patients of reproductive potential must be on an effective contraceptive method\n\nExclusion Criteria:\n\n* Pregnant and\u002For lactating women\n* Patients included in any other interventional trial\n* Use of endotracheal intubation and mechanical ventilation or extracorporeal membrane oxygenation (ECMO) at screening\n* Any concurrent serious medical condition or concomitant medication that would preclude participation in the study including but not limited to:\n\n  * Septic shock as defined by systolic blood pressure (SBP) \\\u003C 90 mmHg or diastolic blood pressure (DBP) of \\\u003C 60 mmHg;\n  * Multiple organ failure;\n  * Are moribund irrespective of the provision of treatments;\n  * Any significant bleeding disorder or vasculitis;\n  * Any serious, nonhealing wound, peptic ulcer or bone fracture;\n  * Liver cirrhosis;\n  * History of a hypertensive crisis or hypertensive encephalopathy, or current, poorly controlled hypertension or hypotension;\n  * Severe renal insufficiency or end stage renal disease as determined by estimated glomerular filtration rate \\\u003C30mL\u002Fmin\u002F1.73m2;\n  * ARDS risk factors of aspiration pneumonia, non-cardiac shock, trauma, blood transfusion or drug overdose.\n* Any thromboembolic event within the past 3 months;\n* Symptomatic congestive heart failure or symptomatic or poorly controlled cardiac arrhythmia \\> class II as per New York Heart Association (NYHA) classification;\n* History of autonomic disorders or uncontrolled hypotension\n* Hypersensitivity to drug products containing polyethylene glycol (PEG)\n* Any other condition which the Principal Investigator feels may jeopardize the safety of the patient or the objectives of the study","ALL","18 Years",{"count":19,"type":20},120,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","A Phase 2a, randomized, double-blind, placebo-controlled, multiple ascending dose study in patients who are hospitalized with presumed pneumonia requiring supplemental oxygen therapy. The purpose of this study is to examine the safety, tolerability and efficacy of AV-001 Injection administration daily to the earlier of day 28 or EOT (day prior to hospital discharge). A total of 120 eligible patients (20 patients in each of cohort 1, 2 and 3 and 60 patients in cohort 4) will be recruited from up to 25 participating institutions\u002Fhospitals. Patients will be randomized in a 1:1 ratio to receive either AV-001 Injection or AV-001 placebo Injection, together with standard of care (SOC).",[26,27,28,29,30,31],"Acute Respiratory Distress Syndrome","Viral or Bacterial Infections","Pneumonia","Pneumonia, Viral","Respiratory Infection","COVID-19 Acute Respiratory Distress Syndrome","RECRUITING","2026-02-24",{"date":35,"type":36},"2026-02-27","ACTUAL",{"date":38,"type":36},"2021-12-20",{"date":40,"type":20},"2026-06",{"name":42,"class":43},"Vasomune Therapeutics, Inc.","INDUSTRY",5,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},"100572670","phase-4-post-authorization-efficacy-and-safety-study-paes-to-confirm-and-collect-more-clinical-data-of-buccalin-tablets-in-the-prophylaxis-of-recurrent-lower-respiratory-tract-infections-rlrtis-100572670","NCT06736288","Post Authorization Efficacy and Safety Study (PAES) to Confirm and Collect More Clinical Data of Buccalin® Tablets In the Prophylaxis of Recurrent Lower Respiratory Tract Infections (RLRTIs).","Randomized, Double Blind, Placebo Controlled, Two-Arms, Multicenter, Post Authorization Efficacy and Safety Study (PAES) to Confirm and Collect More Clinical Data of Buccalin® Tablets In the Prophylaxis of Recurrent Lower Respiratory Tract Infections (RLRTIs).","BUC-01-23","Inclusion Criteria:\n\n1. Patients willing and able to provide voluntary informed consent and to follow protocol requirements.\n2. Male or females from 18 to 99 years old, (Adult, Older Adult).\n3. Patients with Recurrent LRTIs including tracheitis, tracheobronchitis, acute bronchitis and exacerbations of chronic lung disease (asthma and\u002For COPD and\u002For bronchiectasis), who present with both of the following:\n\n   a) ≥2 episodes within 12 months prior to the run-in period based on patient reported medical history (to access the run-in period) b) ≥2 episodes during the run-in period documented by appropriate microbiological diagnostic test (to access the treatment period)\n4. Patients:\n\n   1. not vaccinated or\n   2. vaccinated against the most common pathogens for respiratory infectioan (within 12 months prior to the run-in period or during the run-in period, but not during the treatment period)\\*:\n\n      \\- Anti-pertussis vaccination\n\n      \\- Covid-19 vaccination\n\n      \\- Respiratory Syncytial Virus vaccination\n\n      \\- Influenza vaccination\n\n      \\- Pneumococcal vaccination\n\n      \\* Patients vaccinated with other types of vaccines that have no effect on the lower respiratory tract (e.g. hepatitis b vaccination, shingles\u002Fherpes zoster vaccination, papilloma virus vaccine), in addition to the ones listed above, may also be included.\n\nExclusion Criteria:\n\nRUN-IN period\n\n1. Female patient: pregnant, lactating or planning pregnancy (Female of child-bearing potential will undergo urine pregnancy test).\n2. Female of potential child-bearing that does not use at least one effective contraceptive method for the entire study.\n3. Contraindication or known hypersensitivity to the active ingredients of bacterial lysates or any excipients listed in the ingredients.\n4. Pneumonia (based on the EMA Referral Procedure EMEA\u002FH\u002FA-31\u002F1465).\n5. Known history of tuberculosis and\u002For cystic fibrosis.\n6. Known history of immunodeficiency diseases (e.g., HIV infection, AIDS, or any type of congenital or iatrogenic immune deficiency, including IgA deficiency).\n7. Severe heart failure (NYHA class III and IV).\n8. Haematologic diseases including severe anaemia (defined according to the National Cancer Institute as Hemoglobin \\\u003C 8.0 g\u002FdL).\n9. Renal failure (eGFR \\\u003C 30 mL\u002Fmin).\n10. History of known liver damages defined by the METAVIR classification (F1-F4)\\*.\n11. Malignancies with a remission period of \\\u003C 5 years.\n12. Wheezing documented to be caused by gastroesophageal reflux\\*\\*.\n13. Patient legally or mentally incapacitated unable to give informed consent for the participation in this study.\n14. Patient who is unable or unwilling to comply with the appointments or with all the requirements of the Protocol.\n15. History of autoimmune diseases and acute intestinal infections, as reported in Buccalin® SmPC.\n\n    * This criterion only applies to patients with known liver disease who can produce valid fibroscan and\u002For biopsy results and bring them for demonstration.\n\n      * The criterion can only be applied if the patient presents clinically reliable documentation that the wheezing is not due to a lung disease (i.e. gastroscopy).\n\nTREATMENT period\n\n1. Female patient: pregnant, lactating or planning pregnancy (Female of child-bearing potential will undergo urine pregnancy test).\n2. Female of potential child-bearing that does not use at least one effective contraceptive method for the entire study.\n3. Contraindication or known hypersensitivity to the active ingredients of bacterial lysates or any excipients listed in the ingredients.\n4. Pneumonia (based on the EMA Referral Procedure EMEA\u002FH\u002FA-31\u002F1465).\n5. Known history of tuberculosis and\u002For cystic fibrosis.\n6. Known history of immunodeficiency diseases (e.g., HIV infection, AIDS, or any type of congenital or iatrogenic immune deficiency, including IgA deficiency).\n7. Severe heart failure (NYHA class III and IV).\n8. Haematologic diseases including severe anaemia (defined according to the National Cancer Institute Hemoglobin \\\u003C 8.0 g\u002FdL).\n9. Renal failure (eGFR \\\u003C 30 mL\u002Fmin).\n10. History of known liver damages defined by the METAVIR classification (F1-F4)\\*.\n11. Malignancies with a remission period of \\\u003C 5 years.\n12. Injection or oral administration of steroids within 4 weeks prior to randomization\\*\\*.\n13. Use of immunosuppressants, immunostimulants, or gamma globulins within 6 months prior to randomization.\n14. Previous use within 6 months prior to randomization or ongoing use of bacterial lysates.\n15. Any major surgery within the last 3 months prior to randomization.\n16. Wheezing documented to be caused by gastroesophageal reflux\\*\\*\\*.\n17. Patient legally or mentally incapacitated unable to give informed consent for the participation in this study.\n18. Patient who is unable or unwilling to comply with the appointments or with all the requirements of the Protocol.\n19. History of autoimmune diseases and acute intestinal infections, as reported in Buccalin® SmPC.\n\n    * This criterion only applies to patients with known liver disease who can produce valid fibroscan and\u002For biopsy results and bring them for demonstration.\n\n      * In these instances, patients may undergo a washout period of 4 weeks to qualify for the treatment period.\n\n        * The criterion can only be applied if the patient presents clinically reliable documentation that the wheezing is not due to a lung disease (i.e. gastroscopy).","99 Years",{"count":55,"type":20},240,[57],"PHASE4","The goal of this clinical trial is to assess if BUCCALIN® works In the Prophylaxis of Recurrent Lower Respiratory Tract Infections (RLRTIS). It will also evaluate the safety of BUCCALIN®.\n\nThe primary aim is to reduce the number of infection episodes in the treatment period (12 months) in the BUCCALIN® group versus the Placebo group.\n\nPatients diagnosed with RLRTIS will be screened for enrolment. Patients will be requested to provide informed consent before the start of the study related assessments.\n\nEligible patients who meet the study inclusion and exclusion criteria will be randomized with a 1:1 ratio allocation to the 2 treatment groups.\n\nResearchers will compare BUCCALIN® (gastro-resistant tablets) to a placebo (gastro-resistant tablets containing only excipients) to treat RLRTIS.\n\nPatients who participate in the study will perform several study visits divided as reported below:\n\n* Run-in phase (12 months): patients will not receive any treatment. This phase is designed to increase adherence to the study and reduce loss to follow-up in the clinical trial. During this phase, patients should experience ≥ 2 episodes of RTIs to be eligible for the Treatment period.\n* Treatment period (12 months): patients will receive BUCCALIN® or Placebo treatment for 12 consecutive months (3 days per month, posology as per authorized SmPC).\n* Follow-up period (12 months): patients will not receive any treatment. This phase is designed to observe how patients respond to treatments.",[30,60],"Lower Respiratory Tract Infection (LRTI)","2025-12-03",{"date":63,"type":36},"2025-12-10",{"date":65,"type":36},"2025-10-21",{"date":67,"type":20},"2029-04",{"name":69,"class":43},"Laboratorio Farmaceutico SIT srl",10,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":81,"conditions":82,"keywords":85,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":5},"100609939","prospective-clinical-evaluation-of-the-biofire-emerging-coronavirus-panel-for-the-detection-of-covid-19-and-other-coronaviruses-100609939","NCT07221097","Prospective Clinical Evaluation of the BioFire Emerging Coronavirus Panel for the Detection of COVID-19 and Other Coronaviruses","Prospective Clinical Evaluation of the BioFire Emerging Coronavirus Panel - Sponsor's Protocol","Inclusion Criteria:\n\n* Specimen is residual NPS in transport medium (VTM or UTM) left over from standard of care testing under clinician order for respiratory pathogen analysis.\n* Specimen has been held at room temperature for less than or equal to 4 hours or 4°C for less than or equal to 72 hours before enrollment.\n* At least 1.7 mL of specimen is remaining after standard of care testing and available for use in the study\n\nExclusion Criteria:\n\n* Specimen is unable to be tested within the defined storage parameters\n* Insufficient specimen volume for testing\n* Transport medium type is unknown",{"count":79,"type":20},1500,"OBSERVATIONAL","The Biomedical Advanced Research and Development Authority (BARDA) has contracted BioFire Defense (BFDf) to develop the BioFire Emerging Coronavirus (ECoV) Panel, a nucleic acid test capable of detecting coronaviruses from nasopharyngeal swab (NPS) in transport medium.\n\nThis study aims to evaluate the diagnostic accuracy of the assays comprising the BioFire ECoV Panel. It is hypothesized that the BioFire ECoV Panel assays will be highly sensitive and specific for the detection of the coronaviruses included on the panel.",[83,30,84],"Coronavirus","COVID",[86,87,88,89,90],"in vitro diagnostic","pandemic preparedness","medical device","molecular diagnostic","coronavirus","2025-10-23",{"date":93,"type":36},"2025-10-27",{"date":95,"type":36},"2025-09-29",{"date":97,"type":20},"2026-08",{"name":99,"class":43},"BioFire Defense LLC",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":16,"minAge":108,"maxAge":109,"enrollmentInfo":110,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":112,"conditions":113,"keywords":114,"overallStatus":116,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":4},"100558845","analysis-of-nasopharyngeal-microbiota-in-patients-with-respiratory-infections-100558845","NCT06556420","Analysis of Nasopharyngeal Microbiota in Patients With Respiratory Infections","Analisi Del Microbiota Nasofaringeo in Pazienti Con Infezioni Respiratorie","MINIPAR","Inclusion Criteria:\n\n* age 0-20 years\n* signs and\u002For symptoms of acute respiratory tract infection such as cold, pharyngitis, laryngitis, tracheitis, otitis, epiglottitis, laryngotracheitis, bronchitis and pneumonia.\n\nExclusion Criteria:\n\n* antibiotic therapies in the last 30 days\n* treatments with prebiotics or probiotics in the last 60 days (in particular containing Streptococcus salivarius)\n* hormone therapies in the last 60 days\n* local therapies in the last 60 days\n* treatments with oral cavity disinfectants in the last 30 days\n* presence of other pre-existing or ongoing respiratory pathologies\n* current severe sepsis (sepsis criteria + organ dysfunction, peripheral hypoperfusion, hypotension)","0 Years","20 Years",{"count":111,"type":20},100,"Respiratory tract infections represent the most frequent infectious pathology in community environments and when of bacterial origin, imply a morbid state generally supported by a pathogenic bacterial species predominant on the commensal flora of the airways. Among the most frequent bacterial infections of the upper respiratory tract in pediatric age we find acute bacterial pharyngitis or pharyngotonsillitis caused by Streptococcus pyogenes (β-hemolytic group A), for which antimicrobial therapy is clearly indicated, and which manifests itself with an onset sudden fever. It should also be remembered that some forms of pharyngitis are caused by Chlamydia pneumoniae, Mycoplasma pneumoniae, Bordetella pertussis and Legionella, commonly responsible for lower respiratory tract infections but recently also associated with upper respiratory tract infections. In childhood, a viral or bacterial infection of the upper respiratory tract (in particular pharyngitis, laryngitis) can easily lead to an infection of the lower respiratory tract (pneumonia). In fact, the inflammatory process triggered by a previous infection, generally viral, determines an impairment of mucociliary clearance which facilitates the proliferation not only of pathogenic bacteria but also of the commensal bacterial flora, normally non-pathogenic. An altered local microbial flora can, therefore, contribute to the pathogenesis of new infections or itself be responsible for invasive infections. The microbiota of the upper airways may therefore be a further factor influencing the susceptibility, frequency and severity of acute respiratory diseases. The oropharyngeal microbiota is in fact made up of numerous bacterial species which, by colonizing this anatomical tract, interact with the mucosa of the pharynx and therefore with the immune system, contributing to the homeostasis of the upper respiratory tract and consequently also preserving the integrity of the lower respiratory tract. As observed for other anatomical sites, the composition of the oropharyngeal microbiota is conditioned by external events, among which we find the use of antibiotics or oral disinfectant drugs which can favor the development of pathogenic microorganisms. Characterizing the oropharyngeal microbiota in a state of acute and\u002For chronic respiratory infection could increase knowledge on the microbiological signature associated with such infections and ineffective antibiotic treatments. Greater knowledge of it, also with future corrective purposes, as has now been demonstrated for other body areas, could be of great help in reducing the risk of acute recurrent disease and\u002For chronic consequences.",[30],[115],"microbiota faringeo, infezioni respiratorie","NOT_YET_RECRUITING","2024-08-13",{"date":119,"type":36},"2024-08-16",{"date":121,"type":20},"2024-09-15",{"date":123,"type":20},"2026-08-15",{"name":125,"class":126},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","OTHER",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":135,"sex":16,"minAge":136,"maxAge":137,"enrollmentInfo":138,"targetDuration":4,"studyType":21,"phases":140,"briefSummary":142,"conditions":143,"keywords":150,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":166},"100546126","nationwide-research-on-the-rewilding-of-kindergarten-yards-100546126","NCT06390878","Nationwide Research on the Rewilding of Kindergarten Yards","Nationwide Research on the Rewilding of Kindergarten Yards - Vahvistu","Vahvistu","Inclusion Criteria:\n\n* Attendance in kindergarten\n\nExclusion Criteria:\n\n* Use of antibiotics in the year before sampling",true,"1 Year","5 Years",{"count":139,"type":20},320,[141],"NA","Biodiversity is essential for nature and human well-being. Land use has reduced biodiversity in cities that is associated with altered commensal microbiota and a rising burden of immunological disorders among urban children.\n\nThe investigators will estimate how rewilding of kindergarten yards affects commensal microbiome, prevalence of allergies, asthma, atopic dermatitis and infections, cortisol levels, cognitive skills and plasma cytokine levels of children.\n\nOur specific aims are:\n\nTo assess if rewilding diversifies health-associated skin, saliva and gut microbiota and reduces infectious diseases and atopic or allergic symptoms.\n\nAssess whether the rewilding has positive effects on cognitive skills. Assess whether the rewilding changes cortisol and plasma cytokine levels. The investigators will recruit altogether 320 (160 per treatment) study subjects aged between 1-5 to questionnaire study (Task 2), from which 120 study subjects will be analyzed more detailed using microbiological and blood samples (Task 1).",[144,145,146,147,148,30,149],"Microbial Colonization","Atopic Dermatitis","Asthma in Children","Allergy","Cognitive Change","Nature, Human",[151,152,153,154,155],"Commensal microbiome","Atopy","Planetary health","Biodiversity","Cognitive skills","2024-06-20",{"date":158,"type":36},"2024-06-24",{"date":160,"type":36},"2024-05-15",{"date":162,"type":20},"2027-08-30",{"name":164,"class":165},"Natural Resources Institute Finland","OTHER_GOV",2,{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":175,"conditions":176,"keywords":178,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":195},"100505363","early-diagnosis-of-invasive-lung-aspergillosis-100505363","NCT05860387","Early Diagnosis of Invasive Lung Aspergillosis","Inclusion Criteria:\n\n* respiratory rate ≥ 30 breaths\u002Fmin\n* PaO2\u002FFiO2 ratio ≤ 250\n* multilobar infiltrates\n* confusion\u002Fdisorientation\n* uremia (blood urea nitrogen level ≥ 20mg\u002FdL)\n* leucocytosis (white blood cell count \\> 12000\u002FmL) or\n* leukopenia (white blood cell count \\\u003C 4 x 109\u002FL)\n* thrombocytopenia (platelet count \\\u003C 100 x 109\u002FL)\n* hyperthermia (core temperature \\> 38 °C)\n* hypothermia (core temperature \\\u003C 36 °C)\n* hypotension requiring aggressive fluid resuscitation\n* invasive mechanical ventilation and septic shock requiring vasopressors\n* Bronchoalveolar Lavage Fluid (BALF) and\u002For Endotracheal Aspirate (ETA)\n\nExclusion Criteria:\n\n\\- patients, in whom PTX3, Aspergillus qPCR, and HPLC-FTICR were not performed or were performed after the start of antifungal treatment",{"count":174,"type":20},150,"The last decade has seen a significant increase in secondary Aspergillus infections, not only due to primary hypersensitivity, and immunodeficiency based on oncological diseases and their therapy, but mainly due to a rise in severe respiratory infections (H1N1, COVID-19, bacterial infections). This is most evident in critically ill patients whose life is threatened by invasive pulmonary aspergillosis (IPA), with over 90 % of cases being caused by Aspergillus fumigatus. In recent decades, various biomarkers with well-known limits of use (Aspergillus DNA, galactomannan, 1,3-ß-D-glucan) have been used for early diagnosis of IPA. However, the clinical need to clearly distinguish the onset of IPA from colonization is much more significant. The current biomarkers only provide \"probable IPA\" interpretation, and the diagnosis is rarely confirmed. Based on our preliminary studies, the use of new low molecular weight substances (secondary metabolites) combined with acute-phase proteins (pentraxin 3) allows very reliable immediate confirmation of IPA. In tissue samples, bronchoalveolar lavage fluid, endotracheal aspirate, breath condensate, serum, and urine of critically ill patients, the investigators will be able to recognize and confirm IPA in time using highly sensitive mass spectrometry detecting specific microbial siderophores in correlation with a significantly increased concentration of acute-phase host protein (pentraxin 3) within hours of the beginning of the invasion of lung tissue. Through a prospective multicentre study, the investigators will evaluate the benefit of new biomarkers in non-invasive IPA confirmation, improve the IPA diagnostic algorithm and transfer the detection method to MALDI-TOF spectrometers widely used in Clinical laboratories in the Czech Republic. In MALDI-TOF mass spectrometry, the ion source is matrix-assisted laser desorption\u002Fionization (MALDI), and the mass analyser is a time-of-flight (TOF) analyser.\n\nThe study results will contribute to a high clarity of IPA cases, the accurate introduction of antifungal therapy, and a better prognosis of survival of critically ill patients.",[30,177],"Invasive Pulmonary Aspergillosis",[179,180,181,182,183,184,185],"biomarkers","qualitative polymerase chain reaction (qPCR)","metallomics","mass spectrometry","colonisation","invasive pulmonary aspergillosis","Pentraxin-3","2023-09-06",{"date":188,"type":36},"2023-09-07",{"date":190,"type":36},"2023-05-31",{"date":192,"type":20},"2026-12-31",{"name":194,"class":126},"University Hospital Ostrava",7]